RIGEL PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Mar 4, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 4, 2025

RIGL$42.05+6.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(In thousands, except share and per share amounts)


· · As of December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$56,746		$32,786
Short-term investments	20,575		24,147
Accounts receivable, net	41,615		30,550
Inventories	6,002		5,522
Prepaid and other current assets	10,165		6,261
Total current assets	135,103		99,266
Property and equipment, net	92		165
Intangible assets, net	27,100		13,878
Operating lease right-of-use assets	246		861
Other assets	1,435		3,055
Total assets	$163,976		$117,225
Liabilities and stockholders’ equity (deficit)
Current liabilities:
Accounts payable	$3,339		$7,142
Accrued compensation	10,139		8,676
Accrued research and development	4,073		3,513
Revenue reserves and refund liability	26,440		15,684
Loans payable, net, current portion	7,272		7,229
Other accrued liabilities	10,396		5,334
Deferred revenue	1,355		1,355
Lease liabilities, current portion	285		692
Other long-term liabilities, current portion	—		3,642
Total current liabilities	63,299		53,267
Acquisition-related liabilities	5,000		—
Long-term portion of lease liabilities	—		285
Long-term portion of loans payable, net	52,408		52,373
Other long-term liabilities	39,981		39,944
Total liabilities	160,688		145,869

Commitments

Stockholders’ equity (deficit):
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2024 and 2023	—		—
Common stock (1), $0.001 par value; 400,000,000 shares authorized; 17,710,216 and 17,482,513 shares issued and outstanding as of December 31, 2024 and 2023, respectively	18		17
Additional paid-in capital (1)	1,393,325		1,378,881
Accumulated other comprehensive income	10		8
Accumulated deficit	(1,390,065)		(1,407,550)
Total stockholders’ equity (deficit)	3,288		(28,644)
Total liabilities and stockholders’ equity (deficit)	$163,976		$117,225

(1)	Shares issued and outstanding, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the 1-for-10 reverse stock split effected on June 27, 2024 on a retroactive basis for the respective periods presented.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.